<div id="readability-page-1"><div><ul> <li>Earlier this month, Teva Pharmaceutical Industries reported its third quarter 2025 earnings, showing a return to profitability with net income of US$433 million and reaffirmed revenue targets for its key branded product, AUSTEDO, projecting US$2.5 billion in 2027 and peak sales above US$3 billion.</li> <li>The company also adjusted its 2025 full-year revenue guidance downward while disclosing increased intangible asset impairments, highlighting both strengthened near-term financial control and ongoing challenges.</li> <li>We'll now examine how Teva's renewed profitability and updated guidance on AUSTEDO shape its investment outlook for the coming years.</li> </ul><p>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.</p><h2>Teva Pharmaceutical Industries Investment Narrative Recap</h2><p>To be a shareholder in Teva today, you need to believe in the company’s ability to drive earnings growth and generate consistent returns from its innovative branded product line, especially AUSTEDO, even as the core generics segment faces ongoing stagnation. The latest earnings report signals a return to profitability and confirms AUSTEDO’s importance, but the guidance revision and increased impairments highlight that the short-term success continues to depend primarily on branded drug execution, while the largest near-term risk remains exposure to upcoming price negotiations under the Inflation Reduction Act. Neither recent profitability improvements nor AUSTEDO’s updated targets significantly change the profile of these catalysts and risks right now.</p> <p>Among the recent announcements, the full FDA approval and launch of UZEDY for maintenance treatment of bipolar I disorder in adults is especially relevant. This event further diversifies Teva’s revenue base among innovative products, which could bolster the company’s branded portfolio and help counterbalance pressures from the generics business if execution and adoption proceed as projected, supporting near-term growth momentum.</p> <p>In contrast, investors should also keep in mind the upcoming US policy-driven price challenges around flagship branded treatments like AUSTEDO...</p> <p>Read the full narrative on Teva Pharmaceutical Industries (it's free!)</p><p>Teva Pharmaceutical Industries' outlook anticipates $17.8 billion in revenue and $1.5 billion in earnings by 2028. This scenario requires a 2.3% annual revenue growth rate and an earnings increase of $1.66 billion from current earnings of -$157 million.</p><p>Uncover how Teva Pharmaceutical Industries' forecasts yield a $27.45 fair value, a 8% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/community-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/62486a02-b6f5-48a5-8ffa-0d95e668a50d/chart/community-fair-value"/><figcaption>TEVA Community Fair Values as at Nov 2025</figcaption></figure> <p>Thirteen member-sourced perspectives from the Simply Wall St Community put Teva’s fair value between US$27.45 and US$76.14 per share, underscoring a broad valuation spectrum. With AUSTEDO’s future profits facing potential headwinds from US pricing reforms, it is clear your view on risk will shape your outlook on Teva’s shares.</p><p>Explore 13 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth over 2x more than the current price!</p><h2>Build Your Own Teva Pharmaceutical Industries Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Outshine the giants: these 25 early-stage AI stocks could fund your retirement.</li><li>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</li><li>Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

TEVA

<p>Teva Pharmaceutical Industries reported Q3 2025 earnings with a net income of $433 million, returning to profitability. The company reaffirmed revenue targets for AUSTEDO, projecting $2.5 billion in 2027 and peak sales above $3 billion. However, it adjusted its 2025 full-year revenue guidance downward and disclosed increased intangible asset impairments. The outlook anticipates $17.8 billion in revenue and $1.5 billion in earnings by 2028. The FDA approval and launch of UZEDY for bipolar I disorder is expected to diversify revenue. Risks include US policy-driven price challenges.</p>

Teva (TEVA) Is Up 6.0% After Q3 Profitability Return and Updated AUSTEDO Guidance Has the Bull Case Changed?